GLP1R and type 2 diabetes mellitus: GLP-1 RAs reduce the risk of MACE by 14% compared to placebo in patients with T2DM over a period of 1.3-5.4 years (HR: 0.86; 95% CI: 0.79–0.94; P = 0.006)